APVO
Aptevo Therapeutics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-38/100
Last price
1.80
▼ 0.01 (0.28%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.80
Day high
1.92
Day low
1.79
Volume
35.40K
Market cap
$3.25M
P/E (TTM)
0.03
52W range
1.37 – 33.12
Trailing performance
Returnvs SPY
1W
-3.49%
-5.4%
1M
+3.16%
+2.0%
3M
-60.11%
-64.6%
6M
-56.95%
-75.1%
YTD
-80.97%
-95.2%
1Y
-93.03%
-109.4%
3Y
-100.00%
-182.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on APVO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
74.83K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 6, 26 | HARSANYI ZSOLT Director |
— | 400 | — | Direct |
| Aug 6, 26 | TAYLOR DAPHNE L Chief Financial Officer |
— | 638 | — | Direct |
| Aug 6, 26 | WHITE MARVIN L Officer and Director |
— | 1.67K | — | Direct |
| Aug 6, 26 | NIEDERHUBER JOHN Director |
— | 400 | — | Direct |
| Aug 6, 26 | LAMOTHE JEFFREY G Chief Executive Officer |
— | 961 | — | Direct |
| Aug 6, 26 | GRANT GRADY III Director |
— | 400 | — | Direct |
| Aug 6, 26 | KUNZ BARBARA LOPEZ Director |
— | 400 | — | Direct |
| Aug 6, 26 | ABDUN-NABI DANIEL J Director |
— | 400 | — | Direct |
| Aug 6, 26 | HUEBNER DIRK Officer |
— | 638 | — | Direct |
| Aug 6, 26 | KWON SOYOUNG General Counsel |
— | 638 | — | Direct |
| Nov 10, 25 | GRANT GRADY III Director |
BUY | 13.51K | $20.13K | Direct |
| Jul 17, 25 | HARSANYI ZSOLT Director |
— | 1 | — | Direct |
| Jul 17, 25 | TAYLOR DAPHNE L Chief Financial Officer |
— | 3 | — | Direct |
| Jul 17, 25 | WHITE MARVIN L Chief Executive Officer |
— | 10 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ABDUN-NABI DANIEL J |
Director | 400 | Conversion of Exercise of derivative security |
GRANT GRADY III |
Director | 1.15K | Conversion of Exercise of derivative security |
HARSANYI ZSOLT |
Director | 400 | Conversion of Exercise of derivative security |
HUEBNER DIRK |
Officer | 482 | Conversion of Exercise of derivative security |
KUNZ BARBARA LOPEZ |
Director | 400 | Conversion of Exercise of derivative security |
KWON SOYOUNG |
General Counsel | 638 | Conversion of Exercise of derivative security |
LAMOTHE JEFFREY G |
Chief Executive Officer | 961 | Conversion of Exercise of derivative security |
NIEDERHUBER JOHN |
Director | 400 | Conversion of Exercise of derivative security |
TAYLOR DAPHNE L |
Chief Financial Officer | 638 | Conversion of Exercise of derivative security |
WHITE MARVIN L |
Officer and Director | 1.26K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.25M
Enterprise value$-2.35M
Revenue (TTM)—
Gross profit—
EBITDA$-26.69M
Net income$-26.50M
EPS (TTM)$65.86
Free cash flow$-15.56M
Total cash$9.80M
Total debt$4.21M
Book value / share$4.26
Shares outstanding1.81M
Float1.70M
Short % of float10.99%
Dividend yield0.00%
Beta (5Y)1.68
Valuation & profitability ratios
Trailing P/E0.03
Forward P/E-0.17
PEG ratio—
Price / sales—
Price / book0.42
EV / revenue—
EV / EBITDA0.09
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-420.34%
Return on assets-111.49%
Debt / equity69.67
Current ratio2.08
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $3.11M | — |
| Operating revenue | $0 | $0 | $0 | $3.11M | — |
| Research & development | $14.54M | $14.38M | $17.11M | $17.88M | +1.1% |
| Selling, general & admin | $11.77M | $10.22M | $11.77M | $13.87M | +15.1% |
| Total operating expense | $26.31M | $24.60M | $28.88M | $31.75M | +7.0% |
| Operating income | -$26.31M | -$24.60M | -$28.88M | -$28.64M | -7.0% |
| Pre-tax income | -$25.97M | -$24.13M | -$18.65M | $7.01M | -7.6% |
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | -7.6% |
| Net income to common | -$27.54M | -$24.13M | -$17.41M | $8.03M | -14.1% |
| Basic EPS | -87.27 | -5,956.55 | -527,606.06 | 729,727.27 | +98.5% |
| Diluted EPS | -87.27 | -31,460.23 | -527,606.06 | 729,727.27 | +99.7% |
| EBIT | -$26.31M | -$24.60M | -$28.88M | -$28.64M | -7.0% |
| EBITDA | -$26.07M | -$24.25M | -$28.31M | -$27.74M | -7.5% |
| Basic shares | 315.54K | 4.05K | 33 | 11 | +7,689.1% |
| Diluted shares | 315.54K | 4.05K | 33 | 11 | +7,689.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.62M | $8.71M | $16.90M | $22.64M | — | +148.1% |
| Cash & short-term investments | $21.62M | $8.71M | $16.90M | $22.64M | — | +148.1% |
| Total current assets | $23.08M | $10.66M | $19.07M | $27.45M | — | +116.5% |
| Property, plant & equipment | $4.11M | $4.93M | $5.78M | $6.76M | — | -16.6% |
| Total assets | $27.19M | $15.59M | $24.84M | $34.22M | — | +74.4% |
| Total current liabilities | $6.05M | $6.21M | $7.22M | $8.71M | — | -2.5% |
| Current debt | — | — | — | $2.00M | $11.67M | — |
| Long-term debt | — | — | — | $1.46M | $3.71M | — |
| Total debt | $4.63M | $5.40M | $5.40M | $9.54M | — | -14.2% |
| Total liabilities | $9.81M | $10.84M | $12.62M | $16.24M | — | -9.4% |
| Retained earnings | -$275.12M | -$247.58M | -$223.45M | -$206.04M | — | -11.1% |
| Shareholder equity | $17.38M | $4.75M | $12.22M | $17.97M | — | +265.5% |
| Working capital | $17.03M | $4.45M | $11.84M | $18.74M | — | +282.5% |
| Net tangible assets | $17.38M | $4.75M | $12.22M | $17.97M | — | +265.5% |
| Shares issued | 997.83K | 4.05K | 33 | 11 | — | +24,531.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | — | -7.6% |
| Depreciation & amortisation | $240.00K | $352.00K | $567.00K | $901.00K | — | -31.8% |
| Stock-based compensation | $96.00K | $1.07M | $2.19M | $1.80M | — | -91.0% |
| Change in working capital | -$1.05M | -$2.18M | $2.91M | $2.14M | — | +51.7% |
| Operating cash flow | -$25.59M | -$23.79M | -$11.73M | -$21.02M | — | -7.6% |
| Capital expenditure | — | — | — | -$29.00K | -$713.00K | — |
| Investing cash flow | $0 | $0 | $0 | -$29.00K | — | — |
| Financing cash flow | $38.50M | $15.60M | $6.00M | -$2.62M | — | +146.9% |
| Free cash flow | -$25.59M | -$23.79M | -$11.73M | -$21.05M | — | -7.6% |
| End cash position | $21.62M | $8.71M | $16.90M | $22.64M | — | +148.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $3.70M | $3.92M | $3.54M | $4.04M | $3.33M | — | -5.8% |
| Selling, general & admin | $2.75M | $2.91M | $2.46M | $3.57M | $2.90M | — | -5.7% |
| Total operating expense | $6.44M | $6.84M | $6.00M | $7.61M | $6.23M | — | -5.8% |
| Operating income | -$6.44M | -$6.84M | -$6.00M | -$7.61M | -$6.23M | — | +5.8% |
| Pre-tax income | -$6.36M | -$6.70M | -$5.81M | -$7.55M | -$6.20M | — | +5.1% |
| Net income | -$6.36M | -$6.70M | -$5.81M | -$7.55M | -$6.20M | — | +5.1% |
| Net income to common | -$6.36M | -$6.79M | -$5.90M | -$9.03M | -$6.20M | — | +6.4% |
| Basic EPS | -5.31 | -6.41 | — | -40.14 | -151.29 | -1,581.81 | +17.2% |
| Diluted EPS | -5.31 | -6.41 | — | -40.14 | -151.29 | -1,581.81 | +17.2% |
| EBIT | -$6.44M | -$6.84M | -$6.00M | -$7.61M | -$6.23M | — | +5.8% |
| EBITDA | -$6.41M | -$6.80M | -$5.92M | -$7.56M | -$6.18M | — | +5.7% |
| Basic shares | 1.20M | 1.06M | — | 224.95K | 41.01K | 4.05K | +12.8% |
| Diluted shares | 1.20M | 1.06M | — | 224.95K | 41.01K | 4.05K | +12.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.80M | $14.52M | $21.62M | $21.06M | $9.41M | -32.5% |
| Cash & short-term investments | $9.80M | $14.52M | $21.62M | $21.06M | $9.41M | -32.5% |
| Total current assets | $10.80M | $15.98M | $23.08M | $22.65M | $11.08M | -32.4% |
| Property, plant & equipment | $3.72M | $3.92M | $4.11M | $4.35M | $4.54M | -5.1% |
| Total assets | $14.52M | $19.90M | $27.19M | $27.00M | $15.62M | -27.0% |
| Total current liabilities | $5.19M | $4.76M | $6.05M | $5.61M | $4.89M | +9.0% |
| Total debt | $4.21M | $4.42M | $4.63M | $3.99M | $4.21M | -4.8% |
| Total liabilities | $8.48M | $8.29M | $9.81M | $9.60M | $9.10M | +2.3% |
| Retained earnings | -$288.26M | -$281.91M | -$275.12M | -$269.22M | -$260.19M | -2.3% |
| Shareholder equity | $6.04M | $11.61M | $17.38M | $17.39M | $6.52M | -48.0% |
| Working capital | $5.61M | $11.22M | $17.03M | $17.04M | $6.19M | -50.0% |
| Net tangible assets | $6.04M | $11.61M | $17.38M | $17.39M | $6.52M | -48.0% |
| Shares issued | 1.20M | 1.20M | 997.83K | 767.16K | 179.12K | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.36M | -$6.70M | -$5.81M | -$7.55M | -$6.20M | +5.1% |
| Depreciation & amortisation | $32.00K | $35.00K | $81.00K | $49.00K | $49.00K | -8.6% |
| Stock-based compensation | $58.00K | $57.00K | $2.00K | $77.00K | -$163.00K | +1.8% |
| Change in working capital | $542.00K | -$1.63M | -$602.00K | $1.28M | -$1.05M | +133.2% |
| Operating cash flow | -$5.45M | -$7.96M | -$5.24M | -$6.69M | -$7.09M | +31.5% |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $726.00K | $871.00K | $5.79M | $18.34M | $14.36M | -16.6% |
| Free cash flow | -$5.45M | -$7.96M | -$5.24M | -$6.69M | -$7.09M | +31.5% |
| End cash position | $9.80M | $14.53M | $21.62M | $21.06M | $9.41M | -32.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -6.20 | -5.31 | +14.4% |
| Mar 2026 | -5.60 | -6.41 | -14.5% |
| Dec 2025 | -8.09 | — | — |
| Sep 2025 | -37.62 | -40.14 | -6.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -3.54 | 1 | $0 | 0.0% |
| Next quarter | -2.68 | 1 | $0 | 0.0% |
| Current year | -16.02 | 1 | $0 | 0.0% |
| Next year | -10.40 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$25.50
High target$30.00
Low target$21.00
Implied upside1320.61%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders4.15%
Held by institutions2.88%
Institutions holding11
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.83
-1.99% from price
SMA 20
1.82
-1.32% from price
SMA 50
2.60
-30.93% from price
SMA 100
3.62
-50.45% from price
SMA 200
5.29
-66.05% from price
EMA 12
1.83
-1.96% from price
EMA 26
2.03
-11.72% from price
EMA 50
2.53
-29.12% from price
RSI (14)
35.3
Neutral
MACD (12,26,9)
-0.20
Hist 0.06
ATR (14)
0.09
5.26% of price
Realised vol 30D
132.2%
Annualised
Bollinger upper
1.92
20, 2σ
Bollinger lower
1.72
20, 2σ
50 / 200 cross
Death
2.60 vs 5.29
Trend bias
Below 200
-66.05%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.21
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
132.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-94.6%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.09
5.26% of price
Beta (reported)
1.68
5Y monthly, from filing
Short interest
Shares short
187.94K
Prior 81.75K
Change vs prior
+129.9%
Shorts adding
% of float
10.99%
Elevated
% of shares out
10.38%
Against total outstanding
Days to cover
1.0
Liquid
Float
1.70M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateMar 27, 2020
Last split1:18
Split dateDec 30, 2025
SEC filings
Offering Registrations
S-8 · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-09-24
Corporate Changes & Voting Matters
8-K · 2026-09-23
Proxy Statements
DEF 14A · 2026-08-31
Additional Forms
D · 2026-08-26
Proxy Statements
PRE 14A · 2026-08-21
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-13
Headlines
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
ACCESS Newswire · 13d ago
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
InvestorsHub · 34d ago
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
ACCESS Newswire · 34d ago
APVO: Focusing on Three Key Areas of Development
Zacks Small Cap Research · 44d ago
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
ACCESS Newswire · 54d ago
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
ACCESS Newswire · 55d ago
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
ACCESS Newswire · 56d ago
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
ACCESS Newswire · 72d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.